BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24885324)

  • 1. Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.
    Peng N; Zhang Y; Ma C; Yu MW; Yang GW; Fu Q; Xu WR; Wang XM
    Trials; 2014 May; 15():171. PubMed ID: 24885324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: A randomized, controlled clinical trial.
    Peng N; Yu M; Yang G; Fu Q; Xu Y; Yu J; Liu Q; Li C; Xu W; Zhang Y; Ma C; Yang L; Yu R; Wang X
    Breast; 2018 Feb; 37():18-27. PubMed ID: 29059538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese Medicine Yishen Jiangu Granules () on Aromatase Inhibitor-Associated Musculoskeletal Symptoms.
    Zhang X; Peng N; Yu MW; Zhang GL; Sun X; Yang GW; Li C; Yang L; Wang XM
    Chin J Integr Med; 2018 Nov; 24(11):867-872. PubMed ID: 30062634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial.
    Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
    Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of traditional Chinese medicine Shu Gan Jian Pi granules on patients with breast cancer and cancer-related fatigue: study protocol for a randomized controlled trial.
    Li C; Yang G; Yu M; Xu Y; Xue N; Nan N; Wang X
    Trials; 2015 Apr; 16():192. PubMed ID: 25927849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
    Roberts K; Rickett K; Greer R; Woodward N
    Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
    Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
    Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
    Bao T; Cai L; Giles JT; Gould J; Tarpinian K; Betts K; Medeiros M; Jeter S; Tait N; Chumsri S; Armstrong DK; Tan M; Folkerd E; Dowsett M; Singh H; Tkaczuk K; Stearns V
    Breast Cancer Res Treat; 2013 Feb; 138(1):167-74. PubMed ID: 23393007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
    Henry NL; Unger JM; Schott AF; Fehrenbacher L; Flynn PJ; Prow DM; Sharer CW; Burton GV; Kuzma CS; Moseley A; Lew DL; Fisch MJ; Moinpour CM; Hershman DL; Wade JL
    J Clin Oncol; 2018 Feb; 36(4):326-332. PubMed ID: 29136387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer.
    Alhanafy AM; Labeeb A; Khalil A
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3525-3531. PubMed ID: 30583679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms.
    Henry NL; Unger JM; Till C; Crew KD; Fisch MJ; Hershman DL
    JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34901744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
    Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
    Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
    Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
    J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors and musculoskeletal symptoms.
    Khanduri S; Dodwell DJ
    Breast; 2008 Feb; 17(1):76-9. PubMed ID: 17822901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
    Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
    Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
    Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
    Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.
    Crew KD; Capodice JL; Greenlee H; Brafman L; Fuentes D; Awad D; Yann Tsai W; Hershman DL
    J Clin Oncol; 2010 Mar; 28(7):1154-60. PubMed ID: 20100963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.